{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:03:47Z","timestamp":1771553027271,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.critrevonc.2022.103660","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T21:39:20Z","timestamp":1648157960000},"page":"103660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"173","author":[{"given":"Suji","family":"Udayakumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambica","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Everest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa S.","family":"Arciero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seanthel Delos","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Rahmadian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark K.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin K.W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2022.103660_bib1","first-page":"113","article-title":"A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis","volume":"17","author":"Abrahao","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103660_bib2","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103660_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5306\/wjco.v11.i2.53","article-title":"Objective response rate assessment in oncology: current situation and future expectations","volume":"11","author":"Aykan","year":"2020","journal-title":"World J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103660_bib4","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1186\/s12885-020-07690-8","article-title":"Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)","volume":"20","author":"Brueckl","year":"2020","journal-title":"BMC Cancer"},{"issue":"25","key":"10.1016\/j.critrevonc.2022.103660_bib5","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103660_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108749","article-title":"A bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer","volume":"9","author":"Chan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2022.103660_bib7","unstructured":"Clinical Practice Living Guidelines \u2013 Metastatic Non-Small-Cell Lung Cancer | ESMO. \u3008https:\/\/www.esmo.org\/guidelines\/lung-and-chest-tumours\/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer\u3009. Accessed January 5, 2021."},{"key":"10.1016\/j.critrevonc.2022.103660_bib8","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training. https:\/\/training.cochrane.org\/handbook\/current. Accessed January 5, 2021."},{"issue":"May","key":"10.1016\/j.critrevonc.2022.103660_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","article-title":"Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis","volume":"134","author":"Dafni","year":"2019","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103660_bib10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","article-title":"American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes","volume":"32","author":"Ellis","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103660_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6803","article-title":"Comparison of long-term survival benefits in trials of immune checkpoint inhibitor vs non-immune checkpoint inhibitor anticancer agents using ASCO value framework and ESMO magnitude of clinical benefit scale","volume":"2","author":"Everest","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"March 2011","key":"10.1016\/j.critrevonc.2022.103660_bib12","doi-asserted-by":"crossref","first-page":"S1564","DOI":"10.21037\/jtd.2018.01.131","article-title":"Do immune checkpoint inhibitors need new studies methodology?","volume":"10","author":"Ferrara","year":"2018","journal-title":"J. Thorac. Dis."},{"issue":"14","key":"10.1016\/j.critrevonc.2022.103660_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.03136","article-title":"Updated Analysis From KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non \u2013 small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103660_bib14","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2022.103660_bib15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis","volume":"100","author":"Gandini","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2022.103660_bib16","first-page":"12","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"issue":"14","key":"10.1016\/j.critrevonc.2022.103660_bib17","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non\u2013small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update","volume":"38","author":"Hanna","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103660_bib18","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl. J. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2022.103660_bib19","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103660_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Heal."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103660_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/pst.1846","article-title":"Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point","volume":"17","author":"Huang","year":"2018","journal-title":"Pharm. Stat."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103660_bib22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.critrevonc.2022.103660_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.oraloncology.2017.05.011","article-title":"A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN)\u2606","volume":"71","author":"Jerzak","year":"2017","journal-title":"Oral Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103660_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2019.05.009","article-title":"First-line pembrolizumab versus pembrolizumab plus chemotherapy versus chemotherapy alone in non\u2013small-cell lung cancer: a systematic review and network meta-analysis","volume":"20","author":"Kim","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103660_bib25","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/annonc\/mdy075","article-title":"Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer","volume":"29","author":"Liang","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103660_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1746112","article-title":"Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis","volume":"9","author":"Liu","year":"2020","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103660_bib27","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.21037\/jtd.2019.07.45","article-title":"First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis","volume":"11","author":"Liu","year":"2019","journal-title":"J. Thorac. Dis."},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103660_bib28","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat. Med."},{"issue":"16","key":"10.1016\/j.critrevonc.2022.103660_bib29","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat. Med."},{"issue":"10183","key":"10.1016\/j.critrevonc.2022.103660_bib30","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103660_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115065","article-title":"Network meta-analysis using R: a review of currently available automated packages","volume":"9","author":"Neupane","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103660_bib32","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jamaoncol.2017.2797","article-title":"Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol."},{"issue":"October 2019","key":"10.1016\/j.critrevonc.2022.103660_bib33","article-title":"Adjuvant treatment for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis","volume":"145","author":"Parmar","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"21","key":"10.1016\/j.critrevonc.2022.103660_bib34","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103660_bib35","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J. Thorac Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103660_bib36","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103660_bib37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.6004\/jnccn.2019.7362","article-title":"Quantifying the survival benefits of oncology drugs with a focus on immunotherapy using restricted mean survival time","volume":"18","author":"Rahmadian","year":"2020","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"issue":"19","key":"10.1016\/j.critrevonc.2022.103660_bib38","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103660_bib39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103660_bib40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103660_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Stat. Methods Med. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103660_bib42","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/jrsm.1362","article-title":"Estimating hazard ratios from published Kaplan-Meier survival curves: a methods validation study","volume":"10","author":"Saluja","year":"2019","journal-title":"Res. Synth Methods."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103660_bib43","doi-asserted-by":"crossref","DOI":"10.3747\/co.27.6583","article-title":"A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma","volume":"27","author":"Santos","year":"2020","journal-title":"Curr. Oncol."},{"issue":"7387","key":"10.1016\/j.critrevonc.2022.103660_bib44","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"Br. Med. J."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103660_bib45","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/JTO.0b013e3181d3504d","article-title":"Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer?: implications for selection of patients for maintenance therapy","volume":"5","author":"Sun","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103660_bib46","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3390\/ijms20102578","article-title":"Remarkable alteration of PD-L1 expression after immune checkpoint therapy in patients with non-small-cell lung cancer: two autopsy case reports","volume":"20","author":"Takahashi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.critrevonc.2022.103660_bib47","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103660_bib48","unstructured":"Uno H., Tian L., Horiguchi M., Cronin A., Battioui C., Bell J. survRM2: Comparing Restricted Mean Survival Time. https:\/\/cran.r-project.org\/web\/packages\/survRM2\/index.html. Accessed June 18, 2020."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103660_bib49","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103660_bib50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s40425-019-0600-6","article-title":"First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy","volume":"7","author":"Zhou","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822000841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:42:29Z","timestamp":1760902949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822000841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":50,"alternative-id":["S1040842822000841"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103660","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103660"}}